Composition for the treatment and prevention of endothelial dysfunction

• US 20030215430A1
• Filed: 05/14/2003
• Published: 11/20/2003
• Est. Priority Date: 09/07/2001
• Status: Active Grant

• Current Assignee: Edward J. Petrus
• Original Assignee: Edward J. Petrus
• Inventors: Petrus, Edward J.
• Granted Patent: US 6,930,099 B2
• Time in Patent Office: Days
• US Class Current: 424/94.1
• CPC Class Codes: A61K 31/525 Isoalloxazines, e.g. riboflavins, vitamin B2
• CPC Class Codes: A61K 31/60 Salicylic acid; Derivatives thereof
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61K 9/0056 Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Abstract

This invention relates to a method and compositions for the treatment and prevention of disorders associated with endothelial dysfunction consisting of anti-inflammatory agents and dietary supplements.

Claims

1. A composition for the treatment and prevention of endothelial dysfunction in mammals comprising a therapeutically effective amount of anti-inflammatory agents comprising;

acetylsalicylic acid, an amino sugar and a zinc compound, combined with dietary supplements.

2. The amino sugar of claim 1, is selected from a group comprising;

glucosamine, glucosamine hydrochloride, glucosamine sulfate, N-acetylglucosamine and mixtures thereof.

3. The zinc compound of claim 1, is selected from a group comprising;

zinc sulfate, zinc chloride, zinc acetate, zinc phenol sulfonate, zinc borate, zinc bromide, zinc nitrate, zinc glycerophosphate, zinc benzoate, zinc carbonate, zinc carnosine, zinc citrate, zinc hexafluorosilicate, zinc diacetate trihydrate, zinc oxide, zinc peroxide, zinc salicylate, zinc silicate, zinc stannate, zinc tannate, zinc titanate, zinc tetrafluoroborate, zinc gluconate, and zinc glycinate.

4. The dietary supplements of claim 1, are selected from a group comprising:

calcium, potassium, magnesium, coenzyme Q10, arginine, alpha-lipoic acid, Vitamin A, Vitamin B, Vitamin C, Vitamin D, Vitamin E, folic acid, selenium, alpha-lipoic acid, herbs, botanicals and mixtures thereof.

5. The composition of claim 1, is in the form of a powder to accelerate local and systemic absorption.

6. The composition of claim 1, is optionally delivered in the form of a rapidly disintegrating tablet.

7. A composition for the treatment and prevention of endothelial dysfunction in mammals comprising a therapeutically effective amount of anti-hypertensive agents comprising;

dietary supplements, an amino sugar, and a zinc compound.

8. The dietary supplements of claim 7, is selected from a group comprising;

calcium, potassium, magnesium, coenzyme Q10, arginine, alpha-lipoic acid, Vitamin A, Vitamin B, Vitamin C, Vitamin D, Vitamin E, folic acid, selenium, alpha-lipoic acid, herbs, botanicals and mixtures thereof.

9. The amino sugar of claim 7, is selected from a group comprising;

glucosamine, glucosamine hydrochloride, glucosamine sulfate, N-acetylglucosamine and mixtures thereof.

10. The zinc compound of claim 7, is selected from a group comprising;

zinc sulfate, zinc chloride, zinc acetate, zinc phenol sulfonate, zinc borate, zinc bromide, zinc nitrate, zinc glycerophosphate, zinc benzoate, zinc carbonate, zinc carnosine, zinc citrate, zinc hexafluorosilicate, zinc diacetate trihydrate, zinc oxide, zinc peroxide, zinc salicylate, zinc silicate, zinc stannate, zinc tannate, zinc titanate, zinc tetrafluoroborate, zinc gluconate, and zinc glycinate.

11. The composition of claim 7, is delivered in the form of a powder to accelerate local and systemic absorption.

12. The composition of claim 7, is optionally delivered in the form of a rapidly disintegrating tablet.

13. A method for the treatment and prevention of endothelial dysfunction in mammals by administering a therapeutically effective amount of anti-inflammatory agents comprising;

acetylsalicylic acid, an amino sugar and a zinc compound, combined with dietary supplements.

14. The method of claim 13, so that the amino sugar is selected from a group comprising;

glucosamine, glucosamine hydrochloride, glucosamine sulfate, N-acetylglucosamine and mixtures thereof.

15. The method of claim 13, so that the zinc compound is selected from a group comprising;

zinc sulfate, zinc chloride, zinc acetate, zinc phenol sulfonate, zinc borate, zinc bromide, zinc nitrate, zinc glycerophosphate, zinc benzoate, zinc carbonate, zinc camosine, zinc citrate, zinc hexafluorosilicate, zinc diacetate trihydrate, zinc oxide, zinc peroxide, zinc salicylate, zinc silicate, zinc stannate, zinc tannate, zinc titanate, zinc tetrafluoroborate, zinc gluconate, and zinc glycinate.

16. The dietary supplements of claim 13, are selected from a group comprising;

calcium, potassium, magnesium, coenzyme Q10, arginine, alpha-lipoic acid, Vitamin A, Vitamin B, Vitamin C, Vitamin D, Vitamin E, folic acid, selenium, alpha-lipoic acid, herbs, botanicals and mixtures thereof.

17. The method of claim 13, so that the composition is delivered in the form of a powder to accelerate local and systemic absorption.

18. The method of claim 13, so that the composition is optionally delivered in the form of a rapidly disintegrating tablet.

20. The method of claim 13 and 19, wherein the composition may contain one or more active agents selected from a group comprising;

flavorings, sweeteners, pigments, antioxidants, immune stimulants, antibacterial agents, bismuth compounds, and anti-inflammatory agents.

19. A method for the treatment and prevention of endothelial dysfunction in mammals comprising a therapeutically effective amount of anti-hypertensive agents comprising;

dietary supplements, an amino sugar, and a zinc compound.